<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03384238</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-42237</org_study_id>
    <secondary_id>NCI-2017-01943</secondary_id>
    <secondary_id>PANC0028</secondary_id>
    <nct_id>NCT03384238</nct_id>
  </id_info>
  <brief_title>Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery</brief_title>
  <official_title>A Phase I/II Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Pancreas Cancer During Surgical Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eben Rosenthal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 and to&#xD;
      see how well it works in finding cancer in patients with pancreatic cancer who are undergoing&#xD;
      surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and&#xD;
      IRDye800CW, an investigational dye that can be seen using a special camera.&#xD;
      Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in&#xD;
      patients with pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the optimal dose of panitumumab-IRDye800 in identifying pancreatic cancer&#xD;
      compared to surrounding normal tissue in the ex vivo setting as measured by tumor to&#xD;
      background ratio.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety and tolerability of the panitumumab-IRDye800 as an imaging agent in&#xD;
      subjects undergoing resection of pancreatic cancer.&#xD;
&#xD;
      II. Determine whether metastatic lesions, positive lymph node, or residual disease can be&#xD;
      detected by near-infrared (NIR) fluorescence imaging with panitumumab-IRDye800 but not by&#xD;
      white light.&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of panitumumab-IRDye800 followed by a phase&#xD;
      II study.&#xD;
&#xD;
      Patients receive a loading dose of panitumumab intravenously (IV) over 60 minutes, and after&#xD;
      15 minutes of observation, patients then receive panitumumab-IRDye800 IV over 60 minutes on&#xD;
      day 0. Patients then undergo surgical resection 2-5 days after panitumumab-IRDye800&#xD;
      administration with imaging using the Novadaq SPY/LUNA, Novadaq IR9000 fluorescence imaging&#xD;
      system with open field handheld fluorescence imaging camera, and/or pinpoint endoscopic&#xD;
      fluorescence imaging camera, and SurgVision Explorer Air multi spectral fluorescence&#xD;
      reflectance system.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 15 and 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor to background ratio (TBR)</measure>
    <time_frame>1 day</time_frame>
    <description>TBR is defined as fluorescence intensity of tumor tissue compared to that of normal surrounding pancreatic tissue.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Grade 2 or higher AEs determined to be clinically significant and definitely, probably or possibly related to study drug</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Safety events will be recorded over the 30 day observation period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of positive lymph nodes per participant, not detected by white light</measure>
    <time_frame>1 day</time_frame>
    <description>Determine whether positive lymph nodes can be detected by near-infrared (NIR) fluorescence imaging with Panitumumab-IRDye800 but not by white light.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of positive resection margins per participant, not detected by white light</measure>
    <time_frame>1 day</time_frame>
    <description>Determine whether residual disease at resection margins can be detected by near-infrared (NIR) fluorescence imaging with Panitumumab-IRDye800 but not by white light.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. Cohort 1a will receive 25 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1b will receive 50 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab. A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1c will receive 75 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab.A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1d will receive a 50 mg dose of Panitumumab IRDye800 and no test/loading dose. A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2- Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 will receive the optimal dose of Panitumumab-IRDye800 as determined in Cohort 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fluorescence Imaging</intervention_name>
    <description>Undergo fluorescence imaging</description>
    <arm_group_label>Cohort 1a</arm_group_label>
    <arm_group_label>Cohort 1b</arm_group_label>
    <arm_group_label>Cohort 1c</arm_group_label>
    <arm_group_label>Cohort 1d</arm_group_label>
    <arm_group_label>Cohort 2- Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort 1a</arm_group_label>
    <arm_group_label>Cohort 1b</arm_group_label>
    <arm_group_label>Cohort 1c</arm_group_label>
    <arm_group_label>Cohort 1d</arm_group_label>
    <arm_group_label>Cohort 2- Dose Expansion</arm_group_label>
    <other_name>ABX-EGF</other_name>
    <other_name>ABX-EGF Monoclonal Antibody</other_name>
    <other_name>ABX-EGF, Clone E7.6.3</other_name>
    <other_name>MoAb ABX-EGF</other_name>
    <other_name>Monoclonal Antibody ABX-EGF</other_name>
    <other_name>Vectibix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab-IRDye800</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort 1a</arm_group_label>
    <arm_group_label>Cohort 1b</arm_group_label>
    <arm_group_label>Cohort 1c</arm_group_label>
    <arm_group_label>Cohort 1d</arm_group_label>
    <arm_group_label>Cohort 2- Dose Expansion</arm_group_label>
    <other_name>Panitumumab IRDye 800</other_name>
    <other_name>RDye800-Panitumumab Conjugate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically suspected or biopsy-confirmed diagnosis of pancreatic adenocarcinoma&#xD;
&#xD;
          -  Planned standard of care surgery with curative intent for pancreatic adenocarcinoma&#xD;
&#xD;
          -  Life expectancy of more than 12 weeks&#xD;
&#xD;
          -  Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group&#xD;
             (ECOG)/Zubrod level =&lt; 1&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 gm/dL&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Magnesium &gt; the lower limit of normal per institution normal lab values&#xD;
&#xD;
          -  Potassium &gt; the lower limit of normal per institution normal lab values&#xD;
&#xD;
          -  Calcium &gt; the lower limit of normal per institution normal lab values&#xD;
&#xD;
          -  Thyroid-stimulating hormone (TSH) &lt; 13 micro international units/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received an investigational drug within 30 days prior to first dose of&#xD;
             panitumumab-IRDye800&#xD;
&#xD;
          -  Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive&#xD;
             heart failure (CHF); or unstable angina within 6 months prior to enrollment&#xD;
&#xD;
          -  History of infusion reactions to panitumumab or other monoclonal antibody therapies&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Evidence of corrected QT (QTc) prolongation on pretreatment electrocardiography (ECG)&#xD;
             (greater than 440 ms in males or greater than 460 ms in females)&#xD;
&#xD;
          -  Lab values that in the opinion of the physician would prevent surgical resection&#xD;
&#xD;
          -  Patients receiving class IA (quinidine, procainamide) or class III (dofetilide,&#xD;
             amiodarone, sotalol) antiarrhythmic agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Poultsides</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eben Rosenthal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>December 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2017</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Eben Rosenthal</investigator_full_name>
    <investigator_title>Professor of Otolaryngology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

